SGLT2 inhibitors are recommended by the AHA/ACC/HFSA for patients with symptomatic chronic HFrEF, irrespective of the presence of type 2 diabetes. In two clinical trials, the addition of the SGLT2 inhibitors dapagliflozin and empagliflozin to standard therapies for patients with HFrEF resulted in a consistent ~25% relative risk reduction of the primary endpoint of cardiovascular death or hospitalization for heart failure.
SGLT2 inhibitors have also been shown to improve renal outcomes in patients with HFrEF. In trials of empagliflozin and dapagliflozin, no patients without diabetes developed ketoacidosis, although SGLT2 inhibitors do increase the risk for diabetic ketoacidosis in patients with diabetes and other high-risk conditions.
Learn more about the treatment of HFrEF.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Alanna Morris, Michael Weber, Jeffrey J. Hsu. Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF) Treatment Optimization - Medscape - Mar 13, 2023.